Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Biogen Inc. reported Q2 2026 total revenue of $2,736.0 million, up slightly from $2,645.5 million a year earlier. Product revenue was $1,916.4 million, revenue from anti‑CD20 programs $513.5 million, Alzheimer’s collaboration revenue $63.7 million, and contract manufacturing, royalty and other revenue $242.4 million. Total cost and expense increased to $2,603.6 million from $1,901.5 million, and net income fell to $97.5 million (diluted EPS $0.66) from $634.8 million (EPS $4.33). For the first half of 2026, revenue was $5,213.8 million and net income $417.0 million, versus $5,076.5 million and $875.3 million in 2025.
On May 14, 2026 Biogen completed the $5,410.1 million acquisition of Apellis Pharmaceuticals, paying $41.00 per share in cash plus contingent value rights of up to $4.00 per share tied to SYFOVRE net sales. The deal added completed‑technology intangibles of $4,630.0 million, inventory of $712.0 million and goodwill of $501.5 million, financed with cash, sale of marketable debt securities, a new $2.0 billion 2026 Term Loan and a $400.0 million revolver draw. As of June 30, 2026, cash and cash equivalents were $1,285.0 million, notes payable and term loan totaled $8,090.2 million, and intangible assets, net, were $13,516.4 million. Operating cash flow for the first half was $1,094.4 million. Biogen recorded $173.3 million in restructuring charges year‑to‑date, including about $153.2 million related to Apellis integration, alongside ongoing Fit for Growth cost‑saving measures.
Biogen Inc. reported second quarter 2026 total revenue of $2.736 billion, up 3% year-over-year (2% at constant currency), driven by its Growth Portfolio, which generated $1.06 billion of revenue and grew 24% year-over-year, offsetting declines in multiple sclerosis and biosimilars revenue.
GAAP profitability was sharply lower, with GAAP diluted EPS of $0.66 versus $4.33 a year ago, and Non-GAAP diluted EPS of $3.60 versus $5.47, reflecting higher cost of sales, increased R&D and SG&A, acquired IPR&D, restructuring, and Apellis-related charges. MS product revenue fell 13% to $963 million, while rare disease revenue rose 11% to $602 million. Newly acquired SYFOVRE and EMPAVELI contributed specialized immunology revenue and supported Growth Portfolio expansion.
Biogen updated 2026 guidance, now expecting total revenue to increase by a mid-single digit percentage and guiding Non-GAAP diluted EPS of $12.00–$13.00, down from prior $14.25–$15.25, due to approximately $3.00 of acquired IPR&D and milestone charges and about $0.85 of dilution from the Apellis acquisition. Underlying EPS guidance excluding these items was raised by $0.60 to $15.85–$16.85. Management reiterates expectations for Apellis to be accretive to Non-GAAP EPS in 2027 with at least $250 million of run-rate synergies exiting 2027.
Biogen Inc. is warning that special research and development charges will weigh on its earnings for the middle of 2026. For the second quarter of 2026, it expects acquired in-process research and development, upfront and milestone expense of about $164 million, which management estimates will reduce GAAP and non-GAAP net income by roughly $0.95 per diluted share.
For the third quarter of 2026, Biogen anticipates additional acquired in-process research and development, upfront and milestone expense of $290 million to $320 million, tied to potential milestones and transactions that have not yet closed. This third-quarter expense is expected to lower GAAP and non-GAAP net income by about $1.75 to $1.95 per diluted share. These costs arise from collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions.
BIOGEN INC. director William A. Hawkins reported an equity compensation award rather than an open-market trade. He acquired 1,505 shares of Common Stock at no cost under a grant classified as a “grant, award, or other acquisition.”
After this award, Hawkins directly holds 10,365 Common Stock shares. According to a footnote, the related restricted stock units vest on the earlier of the next annual meeting or the anniversary of the date of grant of June 9, 2026, tying this award to his ongoing board service.
SHERWIN STEPHEN A reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Stephen A. Sherwin reported receiving an equity award of 1,505 shares of common stock on June 9, 2026, at no cash cost to him, as a grant or award. Following this grant, he holds a total of 15,193 common shares directly.
The award consists of restricted stock units that will vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying the compensation to his continued board service over this period.
Rowinsky Eric K reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Eric K. Rowinsky received an equity grant as part of his compensation. He was awarded 1,505 shares of common stock in the form of restricted stock units at a grant price of $0.00 per share.
After this grant, he directly holds 25,844 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying his compensation to the company’s future performance over roughly a one-year period.
Mantas Jesus B reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Jesus B. Mantas reported an equity award of 1,505 shares of Common Stock, received as a grant rather than a market purchase. Following this award, his direct ownership increased to 11,263 shares.
The filing notes that the associated restricted stock units vest on the earlier of the company’s next annual meeting or the anniversary of the June 9, 2026 grant date, tying the award to continued board service over that period.
LANGER SUSAN reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Susan Langer received a grant of 1,505 shares of common stock as a compensation award. The grant was recorded at a price of $0.00 per share, indicating it was not an open-market purchase. After this award, she directly holds 6,634.1 common shares. A footnote explains that the restricted stock units from this grant vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying the award’s vesting to the company’s governance calendar.
Patolawala Monish D reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Monish D. Patolawala received an equity grant of 1,505 shares of Common Stock as a compensation award at no cost. Following this award, he directly holds 5,215 shares. The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date.
BIOGEN INC. director Menelas N. Pangalos reported routine equity compensation activity. He received a grant or award of 1,505 shares of Common Stock at a stated price of $0.00 per share, reflecting stock-based director compensation rather than an open-market purchase.
On the same date, he exercised 2,370 Restricted Stock Units into 2,370 shares of Common Stock, fully settling that RSU award. Following these transactions, his direct holdings of Biogen common stock increased to 3,875 shares. Footnotes state that the restricted stock units vest upon the earlier of the next annual meeting or the first anniversary of their respective grant dates.